NCT01550107

Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength'

A Prospective Study to Evaluate the Effect of Allopurinol on Muscle Energetics in Primary Sarcopenia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 124 (actual)
• Sponsor: University of Dundee · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

Sarcopenia is defined as the presence of low muscle mass and either decreased muscle strength or function. It is increasingly becoming a significant cause of frailty, loss of independence and physical disability in ageing western populations. Recent experimental evidence has revealed that skeletal muscle is particularly susceptible to damaging molecules that result in oxidative stress and that oxidative stress plays a prominent role in the development and progression of sarcopenia. The investigators have previously shown that the xanthine oxidase inhibitor allopurinol is able to abolish vascular oxidative stress and improve endothelial function in cohorts such as optimally treated chronic heart failure and chronic kidney disease. Recently, the investigators have also shown that allopurinol improves exercise tolerance and time to ST-depression in optimally treated coronary artery disease, suggesting that allopurinol could also exert its effects through ATP and/or oxygen sparing mechanisms. Therefore, we propose a randomised double blind placebo-controlled parallel group trial of allopurinol in patients with primary sarcopenia using MR-spectroscopy and Flow Mediated Dilatation to investigate the possible mechanisms that underlie this exciting possibility

Detailed description

this section will be completed once the study is officially recruiting

Conditions

• Sarcopenia

Interventions

Type	Name	Description
DRUG	Allopurinol	300mg b.d for 24 weeks
DRUG	Lactose tablets	matched placebo tablets b.d

Timeline

• Start date: 2015-02-01
• Primary completion: 2017-08-01
• Completion: 2017-09-20
• First posted: 2012-03-09
• Last updated: 2018-03-20

Locations

1 site across 1 country: United Kingdom